首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1461503

抗生素抗藥性全球市場規模、佔有率、成長分析（按藥物類別、病原體、疾病）- 產業預測，2024-2031 年

Global Antibiotic Resistance Market Size, Share, Growth Analysis, By Drug-class, By Pathogen, By Disease - Industry Forecast 2024-2031

出版日期: 2024年04月02日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球抗生素抗藥性市場規模為89.8億美元，從2023年的101.6億美元成長到2031年的273.9億美元，預測期間（2024-2031年）預計年複合成長率為13.19%。

在抗生素抗藥性細菌帶來的日益嚴峻的挑戰的推動下，全球抗生素抗藥性市場正在經歷顯著擴張。該報告對抗生素抗藥性市場的價值鏈進行了詳細分析，並為製造商提供了競爭考察，以在預測期內加強競爭。抗生素抗藥性的普遍存在正在危及感染疾病傳統治療方法的有效性，其主要原因是抗生素的濫用和過度使用。醫療機構感染預防措施不足正在加劇抗藥性菌株的傳播，而正在開發的新抗生素的嚴重短缺更是雪上加霜。認知到這場危機的緊迫性，各國政府、醫療機構和製藥公司擴大聯合起來，透過各種手段對抗抗生素抗藥性。鼓勵官民合作關係旨在刺激抗生素創新，抗生素管理計畫的採用在最佳化抗生素使用和遏制抗藥性方面正在獲得動力。同時，針對醫療保健專業人員和公眾的教育宣傳活動正在努力改善處方實踐並提高對抗生素抗藥性的認知。利用基因組學和蛋白質組學等技術進步有望闡明抗藥性機制和設計新的治療方法。噬菌體療法和免疫療法等新選擇描述了對抗抗生素抗藥性的潛在解決方案。抗生素抗藥性情況既帶來了挑戰，也帶來了機遇，齊心協力對於減輕不斷升級的威脅並保障未來有效的細菌感染疾病治療至關重要。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2021年）
主要市場參與者所採取的策略
關鍵成功策略
近期市集活動
主要企業市場佔有率（2021年）

主要企業簡介

輝瑞公司（美國）
默克公司（美國）
強生公司（美國）
諾華公司（瑞士）
葛蘭素史克公司（英國）
Achaogen 公司（美國）
Tetraphase Pharmaceuticals, Inc.（美國）
Paratek 製藥公司（美國）
Melinta Therapeutics, Inc.（美國）
西普拉有限公司（印度）
羅氏控股公司（瑞士）
賽諾菲（法國）
禮來公司（美國）
拜耳公司（德國）
Cubist Pharmaceuticals, Inc.（美國）
艾爾建公司（愛爾蘭）
阿斯特捷利康公司（英國）
梯瓦製藥工業股份有限公司（以色列）
邁蘭 NV（美國）
Basilea Pharmaceutica Ltd.（瑞士）

簡介目錄

Product Code: SQMIG35H2182

Global Antibiotic Resistance Market size was valued at USD 8.98 billion in 2022 and is poised to grow from USD 10.16 billion in 2023 to USD 27.39 billion by 2031, growing at a CAGR of 13.19% during the forecast period (2024-2031).

The global market for antibiotic resistance is witnessing significant expansion worldwide, driven by the escalating challenge posed by antibiotic-resistant bacteria. Our comprehensive report offers an in-depth analysis of the Antibiotic Resistance market's value chain, equipping manufacturers with insights to enhance their competitive positioning over the forecasted period. The pervasive issue of antibiotic resistance jeopardizes the efficacy of conventional treatments for infectious diseases, primarily attributed to the rampant misuse and overuse of antibiotics. Inadequate infection prevention measures within healthcare settings further exacerbate the spread of resistant strains, compounded by the alarming shortage of new antibiotics in development. Recognizing the urgency of this crisis, governments, healthcare entities, and pharmaceutical firms are increasingly rallying to combat antibiotic resistance through various means. Encouragement of public-private partnerships aims to stimulate antibiotic innovation, while the adoption of antibiotic stewardship programs gains momentum in optimizing antibiotic usage and curbing resistance. Concurrently, educational campaigns target healthcare practitioners and the general populace to improve prescribing practices and foster awareness about antibiotic resistance. Leveraging technological advancements such as genomics and proteomics holds promise in elucidating resistance mechanisms and devising novel therapeutic approaches. Emerging alternatives like phage therapy and immunotherapy offer potential solutions to counter antibiotic resistance. As the antibiotic resistance landscape presents both challenges and opportunities, concerted efforts are imperative to mitigate its escalating threat and safeguard effective bacterial infection treatment in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibiotic Resistance Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibiotic Resistance Market Segmental Analysis

The global antibiotic resistance market can be segmented based on drug-class, pathogen, disease type, and region. Based on drug class, the market can be divided into beta-lactams, macrolides, tetracyclines, fluoroquinolones, and others. Based on pathogens, the market can be categorized into gram-negative bacteria, gram-positive bacteria, and others. Based on disease types, the market can be categorized into respiratory infections, urinary tract infections, bloodstream infections, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Antibiotic Resistance Market

The escalating prevalence of infections caused by antibiotic-resistant bacteria underscores the urgency for the advancement of viable treatment modalities. With conventional antibiotics waning in efficacy, there arises a pressing need for novel antibiotics and alternative interventions to counteract resistant strains. This imperative propels intensive research and developmental endeavors, resulting in the identification of fresh pharmaceuticals and therapeutic strategies to tackle antibiotic resistance. Furthermore, heightened societal consciousness regarding the grave repercussions of antibiotic resistance has galvanized governmental bodies, healthcare institutions, and pharmaceutical enterprises to dedicate resources and undertake initiatives aimed at mitigating this challenge.

Restraints in the Global Antibiotic Resistance Market

The pipeline for developing novel antibiotics is notably constrained despite the escalating menace of antibiotic resistance. Crafting new antibiotics entails navigating a labyrinth of complexities and challenges, demanding substantial investments, time, and specialized knowledge. Yet, obstacles like exorbitant research and development expenses, regulatory hurdles, and minimal returns on investment have dampened antibiotic innovation. This scarcity of fresh antibiotic options severely impairs our capacity to combat antibiotic-resistant infections, emphasizing the pressing imperative for heightened initiatives and incentives to invigorate antibiotic development.

Market Trends of the Global Antibiotic Resistance Market

The increasing threat of antibiotic resistance has prompted a recognition that conventional antibiotic treatments alone may not effectively tackle the issue. Consequently, there's a movement towards investigating alternative strategies to combat bacterial infections. One prominent approach is the progress in phage therapy, where bacteriophages, viruses that infect and destroy bacteria, are utilized to target and eradicate antibiotic-resistant strains. This innovative method presents a promising avenue for addressing antibiotic resistance by precisely targeting harmful bacteria while preserving the beneficial microbiota.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Antibiotic Resistance Market by Drug-class

Market Overview
Beta-lactams
macrolides
tetracyclines
fluoroquinolones
others

Global Antibiotic Resistance Market by Pathogen

Market Overview
Gram-negative bacteria
gram-positive bacteria

Global Antibiotic Resistance Market by Disease

Market Overview
Respiratory infections
urinary tract infections
bloodstream infections
and others

Global Antibiotic Resistance Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Achaogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetraphase Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Paratek Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Melinta Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cubist Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Basilea Pharmaceutica Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments